<?xml version="1.0" encoding="UTF-8"?>
<TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns="ted/R2.0.9.S02/publication"
            xmlns:n2016="ted/2016/nuts"
            xsi:schemaLocation="ted/R2.0.9.S02/publication TED_EXPORT.xsd"
            VERSION="R2.0.9.S02.E01"
            DOC_ID="055845-2018"
            EDITION="2018026">
   <TECHNICAL_SECTION>
      <RECEPTION_ID>18-049591-001</RECEPTION_ID>
      <DELETION_DATE>20180511</DELETION_DATE>
      <FORM_LG_LIST>DA DE EN ES FI FR EL IT NL PT SV CS ET HU LT LV MT PL SK SL GA BG RO HR </FORM_LG_LIST>
      <COMMENTS>From Convertor</COMMENTS>
   </TECHNICAL_SECTION>
   <LINKS_SECTION>
      <XML_SCHEMA_DEFINITION_LINK xlink:type="simple"
                                  xlink:href="http://ted.europa.eu"
                                  xlink:title="TED WEBSITE"/>
      <OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
   </LINKS_SECTION>
   <CODED_DATA_SECTION>
      <REF_OJS>
         <COLL_OJ>S</COLL_OJ>
         <NO_OJ>26</NO_OJ>
         <DATE_PUB>20180207</DATE_PUB>
      </REF_OJS>
      <NOTICE_DATA>
         <NO_DOC_OJS>2018/S 026-055845</NO_DOC_OJS>
         <URI_LIST>
            <URI_DOC LG="DA">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:DA:HTML</URI_DOC>
            <URI_DOC LG="DE">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:DE:HTML</URI_DOC>
            <URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:EN:HTML</URI_DOC>
            <URI_DOC LG="ES">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:ES:HTML</URI_DOC>
            <URI_DOC LG="FI">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:FI:HTML</URI_DOC>
            <URI_DOC LG="FR">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:FR:HTML</URI_DOC>
            <URI_DOC LG="EL">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:EL:HTML</URI_DOC>
            <URI_DOC LG="IT">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:IT:HTML</URI_DOC>
            <URI_DOC LG="NL">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:NL:HTML</URI_DOC>
            <URI_DOC LG="PT">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:PT:HTML</URI_DOC>
            <URI_DOC LG="SV">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:SV:HTML</URI_DOC>
            <URI_DOC LG="CS">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:CS:HTML</URI_DOC>
            <URI_DOC LG="ET">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:ET:HTML</URI_DOC>
            <URI_DOC LG="HU">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:HU:HTML</URI_DOC>
            <URI_DOC LG="LT">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:LT:HTML</URI_DOC>
            <URI_DOC LG="LV">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:LV:HTML</URI_DOC>
            <URI_DOC LG="MT">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:MT:HTML</URI_DOC>
            <URI_DOC LG="PL">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:PL:HTML</URI_DOC>
            <URI_DOC LG="SK">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:SK:HTML</URI_DOC>
            <URI_DOC LG="SL">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:SL:HTML</URI_DOC>
            <URI_DOC LG="GA">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:GA:HTML</URI_DOC>
            <URI_DOC LG="BG">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:BG:HTML</URI_DOC>
            <URI_DOC LG="RO">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:RO:HTML</URI_DOC>
            <URI_DOC LG="HR">http://ted.europa.eu/udl?uri=TED:NOTICE:055845-2018:TEXT:HR:HTML</URI_DOC>
         </URI_LIST>
         <LG_ORIG>EN</LG_ORIG>
         <ISO_COUNTRY VALUE="BE"/>
         <IA_URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</IA_URL_GENERAL>
         <ORIGINAL_CPV CODE="73110000">Research services</ORIGINAL_CPV>
         <n2016:PERFORMANCE_NUTS CODE="BE">BELGIQUE-BELGIË</n2016:PERFORMANCE_NUTS>
         <n2016:CA_CE_NUTS CODE="BE100">Arr. de Bruxelles-Capitale / Arr. van Brussel-Hoofdstad</n2016:CA_CE_NUTS>
         <n2016:TENDERER_NUTS CODE="UK">UNITED KINGDOM</n2016:TENDERER_NUTS>
         <VALUES>
            <VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="EUR">277800.00</VALUE>
         </VALUES>
         <REF_NOTICE>
            <NO_DOC_OJS>2017/S 150-309663</NO_DOC_OJS>
         </REF_NOTICE>
      </NOTICE_DATA>
      <CODIF_DATA>
         <DS_DATE_DISPATCH>20180131</DS_DATE_DISPATCH>
         <AA_AUTHORITY_TYPE CODE="5">European Institution/Agency or International Organisation</AA_AUTHORITY_TYPE>
         <TD_DOCUMENT_TYPE CODE="7">Contract award notice</TD_DOCUMENT_TYPE>
         <NC_CONTRACT_NATURE CODE="4">Services</NC_CONTRACT_NATURE>
         <PR_PROC CODE="1">Open procedure</PR_PROC>
         <RP_REGULATION CODE="3">European Institution/Agency or International Organisation</RP_REGULATION>
         <TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID>
         <AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT>
         <MA_MAIN_ACTIVITIES CODE="S">General public services</MA_MAIN_ACTIVITIES>
         <HEADING>ECC03</HEADING>
         <INITIATOR>EC</INITIATOR>
         <DIRECTIVE VALUE="2014/24/EU"/>
      </CODIF_DATA>
   </CODED_DATA_SECTION>
   <TRANSLATION_SECTION>
      <ML_TITLES>
         <ML_TI_DOC LG="DA">
            <TI_CY>Belgien</TI_CY>
            <TI_TOWN>Bruxelles</TI_TOWN>
            <TI_TEXT>
               <P>Undersøgelse af konsekvensen af fusioner og opkøb for innovation i den farmaceutiske sektor</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DE">
            <TI_CY>Belgien</TI_CY>
            <TI_TOWN>Brüssel</TI_TOWN>
            <TI_TEXT>
               <P>Studie über die Auswirkungen von Fusionen und Übernahmen auf Innovationen im Arzneimittelsektor</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EN">
            <TI_CY>Belgium</TI_CY>
            <TI_TOWN>Brussels</TI_TOWN>
            <TI_TEXT>
               <P>Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ES">
            <TI_CY>Bélgica</TI_CY>
            <TI_TOWN>Bruselas</TI_TOWN>
            <TI_TEXT>
               <P>Estudio sobre las repercusiones de las fusiones y las adquisiciones en materia de innovación en el sector farmacéutico</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FI">
            <TI_CY>Belgia</TI_CY>
            <TI_TOWN>Bryssel</TI_TOWN>
            <TI_TEXT>
               <P>Tutkimus fuusioiden ja yrityskauppojen vaikutuksesta innovointiin lääkealalla</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FR">
            <TI_CY>Belgique</TI_CY>
            <TI_TOWN>Bruxelles</TI_TOWN>
            <TI_TEXT>
               <P>Étude relative à l'impact des activités de fusions et acquisitions sur l'innovation dans le secteur pharmaceutique</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EL">
            <TI_CY>Βέλγιο</TI_CY>
            <TI_TOWN>Βρυξέλλες</TI_TOWN>
            <TI_TEXT>
               <P>Μελέτη σχετικά με τον αντίκτυπο συγχωνεύσεων και εξαγορών για την καινοτομία στον φαρμακευτικό τομέα</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="IT">
            <TI_CY>Belgio</TI_CY>
            <TI_TOWN>Bruxelles</TI_TOWN>
            <TI_TEXT>
               <P>Studio sull'impatto delle fusioni e delle acquisizioni sull'innovazione nel settore farmaceutico</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="NL">
            <TI_CY>België</TI_CY>
            <TI_TOWN>Brussel</TI_TOWN>
            <TI_TEXT>
               <P>Onderzoek naar de gevolgen van fusies en overnames voor innovatie in de farmaceutische sector</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PT">
            <TI_CY>Bélgica</TI_CY>
            <TI_TOWN>Bruxelas</TI_TOWN>
            <TI_TEXT>
               <P>Estudo sobre o impacto das fusões e aquisições na inovação no setor farmacêutico</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SV">
            <TI_CY>Belgien</TI_CY>
            <TI_TOWN>Bryssel</TI_TOWN>
            <TI_TEXT>
               <P>Undersökning avseende effekten av sammanslagningar och förvärv på innovation inom läkemedelssektorn</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="CS">
            <TI_CY>Belgie</TI_CY>
            <TI_TOWN>Brusel</TI_TOWN>
            <TI_TEXT>
               <P>Studie o dopadu fúzí a akvizic na inovace ve farmaceutickém průmyslu</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ET">
            <TI_CY>Belgia</TI_CY>
            <TI_TOWN>Brüssel</TI_TOWN>
            <TI_TEXT>
               <P>Uuring ühinemiste ja omandamiste mõju kohta farmaatsiasektori innovatsioonile</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HU">
            <TI_CY>Belgium</TI_CY>
            <TI_TOWN>Brüsszel</TI_TOWN>
            <TI_TEXT>
               <P>Tanulmány a vállalatfelvásárlások és -összeolvadások által a gyógyszeripari innovációra gyakorolt hatásról</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LT">
            <TI_CY>Belgija</TI_CY>
            <TI_TOWN>Briuselis</TI_TOWN>
            <TI_TEXT>
               <P>Susijungimų ir įsigijimų poveikio inovacijoms farmacijos sektoriuje tyrimas</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LV">
            <TI_CY>Beļģija</TI_CY>
            <TI_TOWN>Brisele</TI_TOWN>
            <TI_TEXT>
               <P>Pētījums par uzņēmumu apvienošanas un pārņemšanas ietekmi uz inovāciju farmācijas nozarē</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="MT">
            <TI_CY>il-Belġju</TI_CY>
            <TI_TOWN>Brussell</TI_TOWN>
            <TI_TEXT>
               <P>Studju dwar l-impatt ta' amalgamazzjonijiet bejn kumpaniji u x-xiri ta' ishma fejn tidħol l-innovazzjoni fis-settur tal-farmaċewtika</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PL">
            <TI_CY>Belgia</TI_CY>
            <TI_TOWN>Bruksela</TI_TOWN>
            <TI_TEXT>
               <P>Badanie dotyczące wpływu połączeń i przejęć na innowacje w sektorze farmaceutycznym</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SK">
            <TI_CY>Belgicko</TI_CY>
            <TI_TOWN>Brusel</TI_TOWN>
            <TI_TEXT>
               <P>Štúdia o dopade fúzií a akvizícií na inovácie vo farmaceutickom sektore</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SL">
            <TI_CY>Belgija</TI_CY>
            <TI_TOWN>Bruselj</TI_TOWN>
            <TI_TEXT>
               <P>Študija o vplivu združitev in prevzemov na inovacije v farmacevtskem sektorju</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="GA">
            <TI_CY>Bheilg, an</TI_CY>
            <TI_TOWN>An Bhruiséil</TI_TOWN>
            <TI_TEXT>
               <P>Staidéar ar thionchar cumasc agus éadálacha ar nuáil san earnáil chógaisíochta</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="BG">
            <TI_CY>Бeлгия</TI_CY>
            <TI_TOWN>Брюксел</TI_TOWN>
            <TI_TEXT>
               <P>Проучване на въздействието на сливането и придобиването на иновации във фармацевтичния сектор</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="RO">
            <TI_CY>Belgia</TI_CY>
            <TI_TOWN>Bruxelles</TI_TOWN>
            <TI_TEXT>
               <P>Studiu privind impactul fuziunilor și a achizițiilor asupra inovării în sectorul farmaceutic</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HR">
            <TI_CY>Belgija</TI_CY>
            <TI_TOWN>Bruxelles</TI_TOWN>
            <TI_TEXT>
               <P>Studija o utjecaju spajanja i preuzimanja vlasništva na inovacije u farmaceutskom sektoru</P>
            </TI_TEXT>
         </ML_TI_DOC>
      </ML_TITLES>
      <ML_AA_NAMES>
         <AA_NAME LG="DA">Europa-Kommissionen, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</AA_NAME>
         <AA_NAME LG="DE">Europäische Kommission; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="EN">European Commission; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="ES">Comisión Europea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="FI">Euroopan komissio, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</AA_NAME>
         <AA_NAME LG="FR">Commission européenne ; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="EL">Ευρωπαϊκή Επιτροπή, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</AA_NAME>
         <AA_NAME LG="IT">Commissione Europea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="NL">Europese Commissie; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="PT">Comissão Europeia, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</AA_NAME>
         <AA_NAME LG="SV">Europeiska kommissionen, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</AA_NAME>
         <AA_NAME LG="CS">Evropská komise; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="ET">Euroopa Komisjon, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</AA_NAME>
         <AA_NAME LG="HU">Európai Bizottság; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="LT">Europos Komisija; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="LV">Eiropas Komisija, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</AA_NAME>
         <AA_NAME LG="MT">Il-Kummissjoni Ewropea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="PL">Komisja Europejska; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="SK">Európska komisia, Directorate-General for Research and Innovation; Directorate E – Health; Unit E.1</AA_NAME>
         <AA_NAME LG="SL">Evropska komisija, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</AA_NAME>
         <AA_NAME LG="GA">An Coimisiún Eorpach; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="BG">Европейска комисия; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="RO">Comisia Europeană; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
         <AA_NAME LG="HR">Europska komisija; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</AA_NAME>
      </ML_AA_NAMES>
   </TRANSLATION_SECTION>
   <FORM_SECTION>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="DA">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europa-Kommissionen, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Undersøgelse af konsekvensen af fusioner og opkøb for innovation i den farmaceutiske sektor</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Formålet med denne undersøgelse er at opnå bedre forståelse af konsekvenserne af fusioner for innovation i den farmaceutiske sektor. Kontrahenten skal analysere mindst 100 tilfælde af fusioner og opkøb i perioden 2010-2013 og studere, hvordan forskellige indikatorer udvikler sig fra 3-4 år før en fusion indtil 3-4 år efter fusionen. Ved at bevæge sig ud over tidligere akademiske arbejder skal kontrahenten ikke kun analysere FoU-investeringer/-intensitet og patenter, men også indikatorer som:</P>
               <P>— antal potentielle lægemidler i forskellige faser af den kliniske udvikling</P>
               <P>— fremskridt på vej</P>
               <P>— antal indstillede programmer grundet resultater af de kliniske forsøg forbundet med dem</P>
               <P>— nye produkters markedsadgang.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Hovedsageligt i kontrahentens lokaler.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Se internetadressen anført i afsnit I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalitet af den foreslåede metodologi</AC_CRITERION>
                  <AC_WEIGHTING>70 point</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Tilrettelæggelse af arbejdet og ressourcerne</AC_CRITERION>
                  <AC_WEIGHTING>20 point</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalitetssikringsforanstaltninger</AC_CRITERION>
                  <AC_WEIGHTING>10 point</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horisont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Se internetadressen anført i afsnit I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Undersøgelse af konsekvensen af fusioner og opkøb for innovation i den farmaceutiske sektor</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Retten</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Se internetadressen anført i afsnit I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="DE">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europäische Kommission; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studie über die Auswirkungen von Fusionen und Übernahmen auf Innovationen im Arzneimittelsektor</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Diese Studie zielt auf ein besseres Verständnis der Auswirkungen von Fusionen auf Innovationen im Arzneimittelsektor ab. Der Auftragnehmer analysiert mindestens 100 Fälle von Fusionen und Übernahmen aus den Jahren 2010-2013 und untersucht, wie sich verschiedene Indikatoren im Zeitraum von 3-4 Jahren vor bis 3-4 Jahre nach der Fusion entwickelt haben. Im Unterschied zu bisherigen wissenschaftlichen Arbeiten analysiert der Auftragnehmer nicht nur Investionen in Forschung und Entwicklung (FuE), die FuE-Intensität und Patente, sondern auch Indikatoren wie:</P>
               <P>— die Anzahl potenzieller Medikamente in verschiedenen klinischen Entwicklungsphasen,</P>
               <P>— Innovationen, an denen gearbeitet wird,</P>
               <P>— Anzahl aufgegebener Programme aufgrund damit zusammenhängender Ergebnisse klinischer Studien,</P>
               <P>— Markteintritt neuer Produkte.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>hauptsächlich in den Räumlichkeiten des Auftragnehmers.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Siehe die in Abschnitt I.3 angegebene Internetadresse.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Qualität der vorgeschlagenen Methodik</AC_CRITERION>
                  <AC_WEIGHTING>70 Punkte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Arbeitsorganisation und Ressourcen</AC_CRITERION>
                  <AC_WEIGHTING>20 Punkte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Qualitätskontrollmaßnahmen</AC_CRITERION>
                  <AC_WEIGHTING>10 Punkte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Siehe die in Abschnitt I.3 angegebene Internetadresse.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studie über die Auswirkungen von Fusionen und Übernahmen auf Innovationen im Arzneimittelsektor</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Gericht</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Siehe die in Abschnitt I.3 angegebene Internetadresse.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="ORIGINAL" FORM="F03" LG="EN">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>European Commission; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>B-1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>This study will aim at better understanding the impacts of mergers on innovation within the pharma sector. The contractor will analyse at least 100 M&amp;A cases from the period 2010-2013, looking at how different indicators evolve from 3-4 years before merger until 3-4 years post-merger. Going beyond previous academic works they will not only analyse R&amp;D investment/intensity and patents but indicators such as:</P>
               <P>— number of drug candidates in various clinical development phases,</P>
               <P>— progress in pipeline,</P>
               <P>— number of discontinued programmes in view of related clinical trial results,</P>
               <P>— market entry of new products.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Mainly at the premises of the contractor.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>See internet address provided in section I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Quality of the proposed methodology</AC_CRITERION>
                  <AC_WEIGHTING>70 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organisation of the work and resources</AC_CRITERION>
                  <AC_WEIGHTING>20 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Quality control measures</AC_CRITERION>
                  <AC_WEIGHTING>10 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizon 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>See internet address provided in section I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>General Court</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>See internet address provided in section I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="ES">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Comisión Europea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Estudio sobre las repercusiones de las fusiones y las adquisiciones en materia de innovación en el sector farmacéutico</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>El presente estudio tiene como objetivo mejorar la comprensión de las repercusiones de las fusiones en materia de innovación dentro del sector farmacéutico. El contratista analizará al menos 100 casos de fusiones y adquisiciones del período 2010-2013, examinando la evolución de diferentes indicadores desde 3-4 años antes de la fusión hasta 3-4 años después de la fusión. Más allá de los trabajos académicos anteriores, no solo se analizarán las patentes y la intensidad/inversión en I+D, sino también indicadores tales como:</P>
               <P>— número de medicamentos candidatos en diversas fases de desarrollo clínico,</P>
               <P>— avances en curso,</P>
               <P>— número de programas interrumpidos en vista de los resultados de ensayos clínicos relacionados,</P>
               <P>— acceso al mercado de nuevos productos.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Principalmente en las instalaciones del contratista.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Véase la dirección de Internet que figura en el apartado I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>calidad de la metodología propuesta</AC_CRITERION>
                  <AC_WEIGHTING>70 puntos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>organización del trabajos y los recursos</AC_CRITERION>
                  <AC_WEIGHTING>20 puntos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>medidas relativas al control de la calidad</AC_CRITERION>
                  <AC_WEIGHTING>10 puntos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizonte 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Véase la dirección de Internet que figura en el apartado I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Estudio sobre las repercusiones de las fusiones y las adquisiciones en materia de innovación en el sector farmacéutico</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunal General</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Véase la dirección de Internet que figura en el apartado I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="FI">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Euroopan komissio, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Tutkimus fuusioiden ja yrityskauppojen vaikutuksesta innovointiin lääkealalla</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Tutkimuksen avulla on tarkoitus ymmärtää paremmin fuusioiden vaikutuksia innovointiin lääkealalla. Sopimusosapuolen on analysoitava vähintään 100 fuusio- ja yrityskauppatapausta (M&amp;A) vuosien 2010–2013 ajalta ja tarkasteltava, miten eri indikaattorit kehittyvät ajanjaksona, joka alkaa 3–4 vuotta ennen fuusiota ja päättyy 3–4 vuotta fuusion jälkeen. Toisin kuin aiemmissa akateemisissa töissä niissä on analysoitava T&amp;K-investointien/intensiteetin ja patenttien lisäksi myös seuraavanlaisia indikaattoreita:</P>
               <P>— kliinisen kehittämisen eri vaiheissa olevien lääke-ehdokkaiden määrä,</P>
               <P>— meneillään oleva kehitys,</P>
               <P>— keskeytettyjen ohjelmien määrä, kun otetaan huomioon niihin liittyvien kliinisten kokeiden tulokset,</P>
               <P>— uusien tuotteiden markkinoille tulo.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>pääasiassa sopimusosapuolen toimitilat.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Katso kohdassa I.3 annettu internetosoite.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>ehdotettujen menetelmien laatu</AC_CRITERION>
                  <AC_WEIGHTING>70 pistettä</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>työn ja resurssien organisointi</AC_CRITERION>
                  <AC_WEIGHTING>20 pistettä</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>laadunvalvontatoimet</AC_CRITERION>
                  <AC_WEIGHTING>10 pistettä</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horisontti 2020 -ohjelma</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Katso kohdassa I.3 annettu internetosoite.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Tutkimus fuusioiden ja yrityskauppojen vaikutuksesta innovointiin lääkealalla</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Unionin yleinen tuomioistuin</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Katso kohdassa I.3 annettu internetosoite.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="FR">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Commission européenne ; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Étude relative à l'impact des activités de fusions et acquisitions sur l'innovation dans le secteur pharmaceutique</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>La présente étude vise à acquérir une meilleure connaissance des répercussions des activités de fusions sur l'innovation dans le secteur pharmaceutique. Le contractant devra analyser au moins 100 cas de fusions et acquisitions portant sur la période 2010-2013 et examiner l'évolution des différents indicateurs à partir des 3-4 ans qui précèdent la fusion jusqu'à 3-4 ans après la fusion. Le contractant devra aller au-delà des précédents travaux universitaires ; il analysera non seulement les investissements dans la R&amp;D/l'intensité des activités de R&amp;D et les brevets, mais aussi des indicateurs tels que :</P>
               <P>— Le nombre de médicaments candidats à différents stades de développement clinique,</P>
               <P>— Les progrès en cours,</P>
               <P>— Le nombre de programmes interrompus compte tenu des résultats des essais cliniques y afférents,</P>
               <P>— L'entrée sur le marché de nouveaux produits.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Principalement dans les locaux du contractant.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Voir adresse Internet indiquée au point I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Qualité de la méthode proposée</AC_CRITERION>
                  <AC_WEIGHTING>70 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organisation du travail et des ressources</AC_CRITERION>
                  <AC_WEIGHTING>20 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Mesures de contrôle de la qualité</AC_CRITERION>
                  <AC_WEIGHTING>10 points</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizon 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Voir adresse Internet indiquée au point I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Étude relative à l'impact des activités de fusions et acquisitions sur l'innovation dans le secteur pharmaceutique</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunal</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Voir adresse Internet indiquée au point I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="EL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Ευρωπαϊκή Επιτροπή, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Μελέτη σχετικά με τον αντίκτυπο συγχωνεύσεων και εξαγορών για την καινοτομία στον φαρμακευτικό τομέα</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Η παρούσα μελέτη στοχεύει στην καλύτερη κατανόηση του αντικτύπου των συγχωνεύσεων για την καινοτομία στον φαρμακευτικό τομέα. Ο ανάδοχος θα αναλύσει τουλάχιστον 100 περιπτώσεις συγχωνεύσεων και εξαγορών από την περίοδο 2010–2013, εξετάζοντας πόσο διαφορετικά εξελίσσονται οι δείκτες από την περίοδο των 3–4 ετών πριν από τη συγχώνευση και 3–4 ετών μετά από τη συγχώνευση. Διαφοροποιούμενοι από προηγούμενα ακαδημαϊκά έργα δεν θα αναλύσουν μόνο δείκτες έντασης/επενδύσεων Έρευνας και Ανάπτυξης και διπλώματα ευρεσιτεχνίας αλλά και δείκτες όπως:</P>
               <P>— αριθμός των υποψήφιων φαρμάκων σε διάφορες φάσεις της κλινικής ανάπτυξης,</P>
               <P>— πρόοδος στο στάδιο επεξεργασίας,</P>
               <P>— αριθμός προγραμμάτων που διακόπηκαν λόγω αποτελεσμάτων από σχετικές κλινικές δοκιμές,</P>
               <P>— είσοδος νέων προϊόντων στην αγορά.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Κυρίως στην έδρα του αναδόχου.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Βλέπε διαδικτυακή διεύθυνση που παρέχεται στο τμήμα I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Ποιότητα της προτεινόμενης μεθοδολογίας</AC_CRITERION>
                  <AC_WEIGHTING>70 βαθμοί</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Οργάνωση της εργασίας και των πόρων</AC_CRITERION>
                  <AC_WEIGHTING>20 βαθμοί</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Μέτρα ποιοτικού ελέγχου</AC_CRITERION>
                  <AC_WEIGHTING>10 βαθμοί</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Ορίζοντας 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Βλέπε διαδικτυακή διεύθυνση που παρέχεται στο τμήμα I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Μελέτη σχετικά με τον αντίκτυπο συγχωνεύσεων και εξαγορών για την καινοτομία στον φαρμακευτικό τομέα</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Γενικό Δικαστήριο</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Βλέπε διαδικτυακή διεύθυνση που παρέχεται στο τμήμα I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="IT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Commissione Europea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studio sull'impatto delle fusioni e delle acquisizioni sull'innovazione nel settore farmaceutico</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Lo studio è rivolto a una migliore comprensione dell'impatto delle fusioni sull'innovazione nel settore farmaceutico. Il contraente analizzerà almeno 100 casi di fusioni e acquisizioni intervenute nel periodo 2010-2013, osservando le modalità di evoluzione di diversi indicatori partendo dai 3–4 anni antecedenti la fusione fino a 3–4 anni successivi alla fusione. Andando oltre ai lavori accademici precedenti, analizzerà non solo gli investimenti/intensità in termini di R&amp;S e i brevetti ma anche indicatori quali:</P>
               <P>— numero di farmaci candidati in varie fasi di sviluppo clinico,</P>
               <P>— progressi nella fase di sperimentazione farmacologica,</P>
               <P>— numero di programmi interrotti in vista dei risultati dei relativi studi clinici,</P>
               <P>— immissione nel mercato di nuovi prodotti.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Principalmente presso le strutture del contraente.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>cfr. indirizzo Internet indicato alla sezione I.3).</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Qualità della metodologia proposta</AC_CRITERION>
                  <AC_WEIGHTING>70 punti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizzazione del lavoro e delle risorse</AC_CRITERION>
                  <AC_WEIGHTING>20 punti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Misure di controllo della qualità</AC_CRITERION>
                  <AC_WEIGHTING>10 punti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Orizzonte 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>cfr. indirizzo Internet indicato alla sezione I.3).</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studio sull'impatto delle fusioni e delle acquisizioni sull'innovazione nel settore farmaceutico</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunale</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>cfr. indirizzo Internet indicato alla sezione I.3).</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="NL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europese Commissie; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Onderzoek naar de gevolgen van fusies en overnames voor innovatie in de farmaceutische sector</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Dit onderzoek beoogt een beter begrip van de gevolgen van fusies voor innovatie in de farmaceutische sector. De contractant moet een analyse maken van minstens 100 gevallen van fusies en overnames uit de periode 2010-2013, om te zien hoe verschillende indicatoren ontwikkelen van 3-4 jaar vóór de fusie tot 3-4 jaar na de fusie. De contractanten moeten verder gaan dan eerder academisch werk en moeten niet enkel de investeringen in en intensiteit van O&amp;O, alsook patenten analyseren maar ook indicatoren zoals:</P>
               <P>— het aantal mogelijke nieuwe geneesmiddelen in verschillende klinische ontwikkelingsfasen,</P>
               <P>— de vooruitgang in de pijplijn,</P>
               <P>— het aantal beëindigde programma's in het licht van de gerelateerde klinische onderzoeksresultaten,</P>
               <P>— de markttoegang van nieuwe producten.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>hoofdzakelijk in de kantoren van de contractant.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Zie het internetadres vermeld in I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>kwaliteit van de voorgestelde methodologie</AC_CRITERION>
                  <AC_WEIGHTING>70 punten</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>organisatie van het werk en de middelen</AC_CRITERION>
                  <AC_WEIGHTING>20 punten</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>maatregelen op het gebied van kwaliteitscontrole</AC_CRITERION>
                  <AC_WEIGHTING>10 punten</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizon 2020.</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Zie het internetadres vermeld in I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Onderzoek naar de gevolgen van fusies en overnames voor innovatie in de farmaceutische sector</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Gerecht</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>zie het internetadres vermeld in I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="PT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Comissão Europeia, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Estudo sobre o impacto das fusões e aquisições na inovação no setor farmacêutico</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Este estudo terá por objetivo uma melhor compreensão dos impactos das fusões na inovação no setor farmacêutico. O contratante analisará pelo menos 100 casos de fusões e aquisições do período 2010-2013, examinando de que forma os diferentes indicadores evoluem de 3-4 anos antes da fusão até 3-4 anos após a fusão. Indo além dos trabalhos académicos anteriores, o contratante analisará não só o investimento/a intensidade de I&amp;D e as patentes, mas também indicadores como:</P>
               <P>— o número de candidatos a medicamentos nas diversas fases de desenvolvimento clínico,</P>
               <P>— o progresso na fase de preparação,</P>
               <P>— o número de programas descontinuados tendo em conta os resultados de ensaios clínicos conexos,</P>
               <P>— a introdução de novos produtos no mercado.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Sobretudo nas instalações do contratante.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Ver endereço Internet disponibilizado no ponto I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Qualidade da metodologia proposta</AC_CRITERION>
                  <AC_WEIGHTING>70 pontos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organização do trabalho e dos recursos</AC_CRITERION>
                  <AC_WEIGHTING>20 pontos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Medidas de controlo da qualidade</AC_CRITERION>
                  <AC_WEIGHTING>10 pontos</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizonte 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Ver endereço Internet disponibilizado no ponto I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Estudo sobre o impacto das fusões e aquisições na inovação no setor farmacêutico</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunal Geral</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Ver endereço Internet disponibilizado no ponto I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="SV">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europeiska kommissionen, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Undersökning avseende effekten av sammanslagningar och förvärv på innovation inom läkemedelssektorn</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Målet med undersökningen är att skapa bättre förståelse för de effekter som sammanslagningar har på innovation inom läkemedelssektorn. Uppdragstagaren ska analysera minst 100 fall av sammanslagningar och förvärv från perioden 2010–2013, och titta på hur olika indikatorer förändras från 3–4 år innan sammanslagningen till 3–4 år efter sammanslagningen. Uppdragstagaren ska röra sig bortom tidigare akademiska arbeten och därmed inte enbart analysera patent och investeringar/intensitet inom ramen för FoU, utan även indikatorer som:</P>
               <P>– antal läkemedelskandidater i olika faser inom klinisk utveckling,</P>
               <P>– framsteg inom pågående kliniska prövningar,</P>
               <P>– antal avslutade program mot bakgrund av de tillhörande resultaten från kliniska prövningar,</P>
               <P>– marknadsinträde för nya produkter.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Huvudsakligen i uppdragstagarens lokaler.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Se internetadressen som anges i punkt I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalitet på den föreslagna metodiken</AC_CRITERION>
                  <AC_WEIGHTING>70 poäng</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organisering av arbetet och resurser</AC_CRITERION>
                  <AC_WEIGHTING>20 poäng</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Åtgärder för kvalitetskontroll</AC_CRITERION>
                  <AC_WEIGHTING>10 poäng</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horisont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Se internetadressen som anges i punkt I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Undersökning avseende effekten av sammanslagningar och förvärv på innovation inom läkemedelssektorn</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunalen</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Se internetadressen som anges i punkt I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="CS">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Evropská komise; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studie o dopadu fúzí a akvizic na inovace ve farmaceutickém průmyslu</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Tato studie se zaměří na lepší pochopení dopadu fúzí na inovace ve farmaceutickém odvětví. Poskytovatel služeb provede analýzu alespoň 100 případů fúzí a akvizic z období let 2010-2013 ve smyslu vývoje různých ukazatelů v rozmezí 3-4 let před fúzí do 3-4 let po fúzi. Měl by jít nad rámec akademických prací a neměl se soustředit pouze na analýzu investic/intenzity výzkumu a vývoje a patenty, ale také na ukazatele, např.:</P>
               <P>— počet uchazečů o lék v různých fázích klinického vývoje,</P>
               <P>— očekávaný pokrok,</P>
               <P>— počet ukončených programů s ohledem na související výsledky klinických studií,</P>
               <P>— tržní vstup nových výrobků.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Zejména v prostorách zhotovitele.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Viz internetová adresa uvedená v oddíle I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalita navrhované metodiky</AC_CRITERION>
                  <AC_WEIGHTING>70 bodů</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizace práce a zdrojů</AC_CRITERION>
                  <AC_WEIGHTING>20 bodů</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Opatření týkající se kontroly kvality</AC_CRITERION>
                  <AC_WEIGHTING>10 bodů</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Viz internetová adresa uvedená v oddíle I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studie o dopadu fúzí a akvizic na inovace ve farmaceutickém průmyslu</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunál</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Viz internetová adresa uvedená v oddíle I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="ET">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Euroopa Komisjon, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Uuring ühinemiste ja omandamiste mõju kohta farmaatsiasektori innovatsioonile</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Uuringu eesmärk on paremini mõista ühinemiste mõju innovatsioonile farmaatsiasektoris. Töövõtja analüüsib vähemalt 100 ühinemise ja omandamise (merger and acquisition (M&amp;A)) juhtumit aastatest 2010-2013 ning uurib seda, kuidas erinevad näitajad arenevad ühinemisele eelnenud 3–4 aastast kuni ühinemisele järgneva 3–4 aastani. Varasematest akadeemilistest uurimustest kaugemale minnes ei analüüsita mitte ainult teadus- ja arendustegevuse investeeringuid/intensiivsust ja patente, vaid ka näiteks järgmisi näitajaid:</P>
               <P>— erinevates kliinilistes arendusetappides olevate potentsiaalsete ravimite arv;</P>
               <P>— edusammud väljatöötamisel;</P>
               <P>— katkestatud programmide arv seoses asjaomaste kliiniliste katsete tulemustega;</P>
               <P>— uute toodete turule viimine.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>peamiselt töövõtja ruumides.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>vt punktis I.3 nimetatud internetiaadressi.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Pakutud metoodika kvaliteet</AC_CRITERION>
                  <AC_WEIGHTING>70 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>töökorraldus ja vahendid</AC_CRITERION>
                  <AC_WEIGHTING>20 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>kvaliteedikontrolli meetmed</AC_CRITERION>
                  <AC_WEIGHTING>10 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horisont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>vt punktis I.3 nimetatud internetiaadressi.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Uuring ühinemiste ja omandamiste mõju kohta farmaatsiasektori innovatsioonile</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Üldkohus</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>vt punktis I.3 nimetatud internetiaadressi.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="HU">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Európai Bizottság; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>B-1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Tanulmány a vállalatfelvásárlások és -összeolvadások által a gyógyszeripari innovációra gyakorolt hatásról</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Jelen tanulmány célja a fúziók által a gyógyszeripari innovációra gyakorolt hatások jobb megértése. A nyertes ajánlattevőnek legalább 100, 2010–2013 közötti vállalatfelvásárlást és -összeolvadást kell elemeznie, megvizsgálva különböző mutatók változását az összeolvadást megelőző 3-4 évtől az azt követő 3-4 évig. A korábbi tudományos munkáktól eltérően nem csak a K+F beruházásokat/intenzitást és szabadalmakat fogja elemezni, de olyan mutatókat is, mint:</P>
               <P>— a különféle klinikai fejlesztési szakaszban lévő gyógyszerjelöltek száma,</P>
               <P>— folyamatban lévő eredmények,</P>
               <P>— a kapcsolódó klinikai teszteredményekre tekintettel félbehagyott programok száma,</P>
               <P>— az új termékek piacra jutása.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Főként a szerződő fél telephelye.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Lásd az I.3. szakaszban megadott internetcímet.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>A javasolt módszertan minősége</AC_CRITERION>
                  <AC_WEIGHTING>70 pont</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>A munka megszervezése és erőforrások</AC_CRITERION>
                  <AC_WEIGHTING>20 pont</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Minőség-ellenőrzési intézkedések</AC_CRITERION>
                  <AC_WEIGHTING>10 pont</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Lásd az I.3. szakaszban megadott internetcímet.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Tanulmány a vállalatfelvásárlások és -összeolvadások által a gyógyszeripari innovációra gyakorolt hatásról</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Törvényszék</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Lásd az I.3. szakaszban megadott internetcímet.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="LT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europos Komisija; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Susijungimų ir įsigijimų poveikio inovacijoms farmacijos sektoriuje tyrimas</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Šio tyrimo tikslas – geriau suprasti susijungimų poveikį inovacijoms farmacijos sektoriuje. Rangovas analizuos bent 100 susijungimų ir įsigijimų atvejų 2010–2013 metų laikotarpiu stebėdamas, kaip skirtingi rodikliai keičiasi nuo 3–4 metų prieš susijungimą iki 3–4 metų po susijungimo. Išskyrus ankstesnius akademinius darbus, jie ne tik analizuos investicijas į mokslinius tyrimus bei plėtrą ir (arba) jų intensyvumą bei patentus, bet ir tokius rodiklius kaip:</P>
               <P>— narkotikų kandidatų skaičius įvairiuose klinikinės raidos etapuose,</P>
               <P>— rengiama pažanga,</P>
               <P>— nutrauktų programų skaičius, atsižvelgiant į susijusius klinikinių tyrimų rezultatus,</P>
               <P>— naujų produktų pateikimas rinkai.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Daugiausia rangovo patalpos.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Žr. interneto adresą, nurodytą I.3 dalyje.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Siūlomos metodikos kokybė</AC_CRITERION>
                  <AC_WEIGHTING>70 balų</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Darbo ir išteklių organizavimas</AC_CRITERION>
                  <AC_WEIGHTING>20 balų</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Kokybės kontrolės priemonės</AC_CRITERION>
                  <AC_WEIGHTING>10 balų</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>„Horizontas 2020“</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Žr. interneto adresą, nurodytą I.3 dalyje.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Susijungimų ir įsigijimų poveikio inovacijoms farmacijos sektoriuje tyrimas</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Bendrasis Teismas</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Žr. interneto adresą, nurodytą I.3 dalyje.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="LV">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Eiropas Komisija, Directorate-General for Research and Innovation, Directorate E – Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Pētījums par uzņēmumu apvienošanas un pārņemšanas ietekmi uz inovāciju farmācijas nozarē</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Šā pētījuma mērķis būs gūt labāku izpratni par uzņēmumu apvienošanas ietekmi uz inovāciju farmācijas nozarē. Darbuzņēmējs analizēs vismaz 100 2010.–2013. gadā notikušas uzņēmumu apvienošanas un pārņemšanas (mergers and acquisitions – M&amp;A) gadījumus, aplūkojot, kā dažādi rādītāji mainās laika posmā, kas sākas 3–4 gadus pirms apvienošanas un beidzas 3–4 gadus pēc apvienošanas. Pētījuma tvērums būs plašāks nekā līdzšinējiem akadēmiskajiem darbiem – darbuzņēmējs analizēs ne tikai ieguldījumus pētniecībā un izstrādē / pētniecības un izstrādes intensitāti un patentus, bet arī tādus rādītājus kā:</P>
               <P>— potenciālo zāļu skaits dažādos klīniskās izstrādes posmos,</P>
               <P>— ražošanas progress,</P>
               <P>— pārtraukto programmu skaits, ņemot vērā saistītos klīnisko pārbaužu rezultātus,</P>
               <P>— jaunu produktu nonākšana tirgū.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>galvenokārt darbuzņēmēja telpās.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Skatīt interneta adresi, kas minēta I.3. iedaļā.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Piedāvātās metodikas kvalitāte</AC_CRITERION>
                  <AC_WEIGHTING>70 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Darba un resursu organizācija</AC_CRITERION>
                  <AC_WEIGHTING>20 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalitātes kontroles pasākumi</AC_CRITERION>
                  <AC_WEIGHTING>10 punkti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>“Apvārsnis 2020”</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Skatīt interneta adresi, kas minēta I.3. iedaļā.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Pētījums par uzņēmumu apvienošanas un pārņemšanas ietekmi uz inovāciju farmācijas nozarē</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Vispārējā tiesa</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Skatīt interneta adresi, kas minēta I.3. iedaļā.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="MT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Il-Kummissjoni Ewropea; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studju dwar l-impatt ta' amalgamazzjonijiet bejn kumpaniji u x-xiri ta' ishma fejn tidħol l-innovazzjoni fis-settur tal-farmaċewtika</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Dan l-istudju se jimmira sabiex wieħed jifhem aħjar l-impatti tal-amalgamazzjonijiet u xiri ta' ishma fi ħdan is-settur tal-farmaċewtika. Il-kuntrattur se janalizza mill-inqas 100 każ ta' Amalgamazzjonijiet&amp;Ksib ta' Ishma fil-perijodu mill-2010 sal-2013, iħares lejn kif indikaturi differenti evolvew fuq medda minn 3-4 snin qabel l-amalgamazzjoni sa 3-4 snin wara l-amalgamazzjoni. Billi jħarsu lil hinn minn xogħlijiet akkademiċi li saru qabel mhux se janalizzaw l-investiment/l-intensità tar-R&amp;Ż u l-brevetti iżda indikaturi bħan-:</P>
               <P>— numru ta' kandidati għall-mediċini f'diversi fażijiet ta' żvilupp kliniku,</P>
               <P>— il-progress li ġej,</P>
               <P>— in-numru ta' programmi li ma tkomplewx fid-dawl tar-riżultati tat-testijiet kliniċi relatati,</P>
               <P>— id-dħul fis-suq ta' prodotti ġodda.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Primarjament fil-bini tal-kuntattur.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Ara l-indirizz tal-Internet ipprovdut fit-taqsima I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Il-kwalità tal-metodoloġija proposta</AC_CRITERION>
                  <AC_WEIGHTING>70 punt</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>L-organizzazzjoni tax-xogħol u r-riżorsi</AC_CRITERION>
                  <AC_WEIGHTING>20 punt</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Il-miżuri tal-kontroll tal-kwalità</AC_CRITERION>
                  <AC_WEIGHTING>10 punti</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizon 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Ara l-indirizz tal-Internet ipprovdut fit-taqsima I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studju dwar l-impatt ta' amalgamazzjonijiet bejn kumpaniji u x-xiri ta' ishma fejn tidħol l-innovazzjoni fis-settur tal-farmaċewtika</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Il-Qorti Ġenerali</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Ara l-indirizz tal-Internet ipprovdut fit-taqsima I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="PL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Komisja Europejska; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Badanie dotyczące wpływu połączeń i przejęć na innowacje w sektorze farmaceutycznym</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Celem badania jest lepsze zrozumienie wpływu połączeń na innowacje w sektorze farmaceutycznym. Wykonawca przeanalizuje co najmniej 100 przypadków połączeń i przejęć, które miały miejsce w latach 2010-2013, z uwzględnieniem zmiany różnych wskaźników w perspektywie czasowej od 3-4 lat przed połączeniem do 3-4 lat po połączeniu. Wykraczając poza wcześniejsze prace akademickie, wykonawca przeanalizuje nie tylko inwestycje/intensywność oraz patenty w sektorze badań i rozwoju, ale również takie wskaźniki jak:</P>
               <P>– liczba nowych modeli leków na różnych etapach rozwoju klinicznego,</P>
               <P>– postępy w ramach procesu,</P>
               <P>– liczba zaniechanych programów w świetle powiązanych wyników badań klinicznych,</P>
               <P>– wprowadzanie na rynek nowych produktów.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Głównie w siedzibie wykonawcy.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Zob. adres internetowy w pkt I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>jakość proponowanej metodyki</AC_CRITERION>
                  <AC_WEIGHTING>70 punktów</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>organizacja pracy i zasobów</AC_CRITERION>
                  <AC_WEIGHTING>20 punktów</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>środki kontroli jakości</AC_CRITERION>
                  <AC_WEIGHTING>10 punktów</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Inicjatywa „Horyzont 2020”</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Zob. adres internetowy w pkt I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Badanie dotyczące wpływu połączeń i przejęć na innowacje w sektorze farmaceutycznym</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Sąd</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Zob. adres internetowy w pkt I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="SK">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Európska komisia, Directorate-General for Research and Innovation; Directorate E – Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Štúdia o dopade fúzií a akvizícií na inovácie vo farmaceutickom sektore</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Cieľom tejto štúdie bude lepšie pochopiť dopady fúzií na inovácie vo farmaceutickom sektore. Dodávateľ bude analyzovať minimálne 100 prípadov fúzií a akvizícií v období rokov 2010 – 2013, zameriavajúc sa na vývoj rôznych ukazovateľov v období 3 – 4 roky pred fúziou a 3 – 4 roky po fúzii. Štúdia bude siahať nad rámec predchádzajúcich akademických prác, pretože nebude analyzovať len investície do výskumu a vývoja a patenty, ale aj ukazovatele ako napríklad:</P>
               <P>— počet nových navrhovaných liekov v rôznych fázach klinického vývoja,</P>
               <P>— očakávaný pokrok,</P>
               <P>— počet ukončených programov vzhľadom na výsledky súvisiacich klinických skúšok,</P>
               <P>— vstup nových výrobkov na trh.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Predovšetkým v priestoroch poskytovateľa služieb.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Pozri internetovú adresu uvedenú v oddiele I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kvalita navrhovanej metodiky</AC_CRITERION>
                  <AC_WEIGHTING>70 bodov</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizácia práce a zdrojov</AC_CRITERION>
                  <AC_WEIGHTING>20 bodov</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Opatrenia na kontrolu kvality</AC_CRITERION>
                  <AC_WEIGHTING>10 bodov</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Horizont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Pozri internetovú adresu uvedenú v oddiele I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Štúdia o dopade fúzií a akvizícií na inovácie vo farmaceutickom sektore</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Všeobecný súd</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Pozri internetovú adresu uvedenú v oddiele I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="SL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Evropska komisija, Directorate-General for Research and Innovation, Directorate E — Health, Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Študija o vplivu združitev in prevzemov na inovacije v farmacevtskem sektorju</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Cilj te študije je bolje razumeti vplive, ki jih imajo združitve na inovacije v farmacevtskem sektorju. Izvajalec bo analiziral najmanj 100 primerov združitev in prevzemov iz obdobja 2010–2013 in raziskal razvoj različnih kazalnikov v obdobju od 3–4 let pred združitvijo do 3–4 let po združitvi. Izvajalec bo presegel predhodna akademska dela in bo poleg naložb/intenzivnosti v zvezi z raziskavami in razvojem ter patentov analiziral tudi kazalnike, kot so:</P>
               <P>— število kandidatov za zdravila v različnih kliničnih razvojnih fazah,</P>
               <P>— napredek v fazi preskušanja zdravila,</P>
               <P>— število programov, ki so bili prekinjeni zaradi rezultatov povezanih kliničnih preskusov,</P>
               <P>— sproščanje novih proizvodov na trg.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>V glavnem v prostorih izvajalca.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Glejte spletni naslov v oddelku I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kakovost predlagane metodologije</AC_CRITERION>
                  <AC_WEIGHTING>70 točk</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizacija dela in virov</AC_CRITERION>
                  <AC_WEIGHTING>20 točk</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Ukrepi za nadzor kakovosti</AC_CRITERION>
                  <AC_WEIGHTING>10 točk</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Obzorje 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Glejte spletni naslov v oddelku I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Študija o vplivu združitev in prevzemov na inovacije v farmacevtskem sektorju</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Splošno sodišče</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Glejte spletni naslov v oddelku I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="GA">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>An Coimisiún Eorpach; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Staidéar ar thionchar cumasc agus éadálacha ar nuáil san earnáil chógaisíochta</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Beidh sé mar aidhm leis an staidéar tuiscint níos fearr a fháil ar thionchair chumasc ar an nuáil laistigh den earnáil chógaisíochta. Déanfaidh an conraitheoir anailís ar 100 cás cumasc agus éadálacha ar a laghad ón tréimhse idir na blianta 2010 agus 2013, ag féachaint ar an gcaoi ina bhforbraíonn táscairí éagsúla ó 3-4 bliana roimh an gcumasc go dtí 3–4 bliana tar éis an chumaisc. Agus céim eile thar shaothair acadúla roimhe seo á glacadh, ní hamháin go ndéanfar anailís ar infheistíocht/déine T&amp;F agus paitinní ach ar tháscairí amhail:</P>
               <P>— líon na ndrugaí is iarrthóirí i gcéimeanna forbartha cliniciúla éagsúla,</P>
               <P>— dul chun cinn sa phíblíne,</P>
               <P>— líon na gclár scortha i bhfianaise torthaí trialacha cliniciúla gaolmhara,</P>
               <P>— táirgí nua a thabhairt chun margaidh.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Ag áitreabh an chonraitheora den chuid is mó.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Féach an seoladh idirlín atá curtha ar fáil in alt I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Cáilíocht na modheolaíochta molta</AC_CRITERION>
                  <AC_WEIGHTING>70 pointe</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Eagrú na hoibre agus na n-acmhainní</AC_CRITERION>
                  <AC_WEIGHTING>20 pointe</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Bearta rialaithe cáilíochta</AC_CRITERION>
                  <AC_WEIGHTING>10 bpointe</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Fís 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Féach an seoladh idirlín atá curtha ar fáil in alt I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Staidéar ar thionchar cumasc agus éadálacha ar nuáil san earnáil chógaisíochta</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>An Chúirt Ghinearálta</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Féach an seoladh idirlín atá curtha ar fáil in alt I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="BG">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Европейска комисия; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>B-1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Проучване на въздействието на сливането и придобиването на иновации във фармацевтичния сектор</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Това проучване ще има за цел по-добро разбиране на въздействието на сливането на иновации в рамките на фармацевтичния сектор. Изпълнителят ще анализира най-малко 100 M&amp;A случая от периода 2010—2013 г., като разгледа как различните показатели са се развили от 3—4 години преди до 3—4 години след сливането. Като излязат извън предходните академични постижения, те не само ще анализират R&amp;D инвестициите/интензитета и патентните, но и показатели като:</P>
               <P>— броя на кандидатите за лекарства в различни фази на клинично развитие,</P>
               <P>— напредъка на снабдителните канали,</P>
               <P>— броя преустановени програми с оглед на резултатите от свързаните клинични изпитвания,</P>
               <P>— навлизането на нови продукти на пазара.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Основно в помещенията на изпълнителя.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Вж. интернет адреса, посочен в раздел I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Качество на предложената методология</AC_CRITERION>
                  <AC_WEIGHTING>70 точки</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Организация на работата и ресурсите</AC_CRITERION>
                  <AC_WEIGHTING>20 точки</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Мерки за контрол на качеството</AC_CRITERION>
                  <AC_WEIGHTING>10 точки</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>„Хоризонт 2020“</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Вж. интернет адреса, посочен в раздел I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Проучване на въздействието на сливането и придобиването на иновации във фармацевтичния сектор</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Общ съд</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Вж. интернет адреса, посочен в раздел I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="RO">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Comisia Europeană; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studiu privind impactul fuziunilor și a achizițiilor asupra inovării în sectorul farmaceutic</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Acest studiu va avea ca scop o mai bună înțelegere a impacturilor fuziunilor asupra inovării în cadrul sectorului farmaceutic. Contractantul va analiza cel puțin 100 de cazuri de fuziuni și achiziții din perioada 2010-2013, examinând modul în care diferiți indicatori evoluează în ultimii 3-4 ani înainte de fuziune până în următorii 3-4 ani după fuziune. Incluzând mai mult decât lucrările academice anterioare, acesta nu va analiza numai investițiile în cercetare și dezvoltare/intensitatea activităților de cercetare și dezvoltare, ci și indicatori cum ar fi:</P>
               <P>— numărul de medicamente candidate din diferite etape ale dezvoltării clinice,</P>
               <P>— progresul în curs,</P>
               <P>— numărul de programe întrerupte ținând cont de rezultatele testelor clinice conexe,</P>
               <P>— intrarea pe piață a noilor produse.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>În principal, la sediul contractantului.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>A se vedea adresa de internet indicată în secțiunea I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Calitatea metodologiei propuse</AC_CRITERION>
                  <AC_WEIGHTING>70 de puncte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizarea activităților și a resurselor</AC_CRITERION>
                  <AC_WEIGHTING>20 de puncte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Măsurile de control al calității</AC_CRITERION>
                  <AC_WEIGHTING>10 puncte</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Orizont 2020</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>A se vedea adresa de internet indicată în secțiunea I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studiu privind impactul fuziunilor și a achizițiilor asupra inovării în sectorul farmaceutic</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Tribunalul</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>A se vedea adresa de internet indicată în secțiunea I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
      <F03_2014 CATEGORY="TRANSLATION" FORM="F03" LG="HR">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europska komisija; Directorate-General for Research and Innovation; Directorate E — Health; Unit E.1</OFFICIALNAME>
               <TOWN>Brussels</TOWN>
               <POSTAL_CODE>B-1049</POSTAL_CODE>
               <COUNTRY VALUE="BE"/>
               <E_MAIL>RTD-PROCUREMENTS-AWARD@ec.europa.eu</E_MAIL>
               <n2016:NUTS CODE="BE100"/>
               <URL_GENERAL>https://etendering.ted.europa.eu/cft/cft-display.html?cftId=2798</URL_GENERAL>
               <URL_BUYER>http://ec.europa.eu/research/index.cfm?pg=tenders-open</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
            <CA_TYPE VALUE="EU_INSTITUTION"/>
            <CA_ACTIVITY VALUE="GENERAL_PUBLIC_SERVICES"/>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studija o utjecaju spajanja i preuzimanja vlasništva na inovacije u farmaceutskom sektoru</P>
            </TITLE>
            <REFERENCE_NUMBER>2017/RTD/E.1/OP/PP-06021-2017</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73110000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Cilj ove studije bolje je razumjeti utjecaje spajanja na inovacije unutar farmaceutskog sektora. Ugovaratelj će analizirati barem 100 slučajeva spajanja i preuzimanja vlasništva (mergers and acquisitions – M&amp;A) iz razdoblja 2010.-2013., razmatrajući kako se različiti pokazatelji razvijaju 3–4 godine prije spajanja do 3–4 godine poslije spajanja. Nadilazeći prethodne akademske radove, neće analizirati samo ulaganje/intenzitet u području istraživanja i razvoja i patente nego i pokazatelje poput:</P>
               <P>— broja kandidata za lijekove u raznim fazama kliničkog razvoja,</P>
               <P>— napretka u sustavu opskrbe,</P>
               <P>— broja obustavljenih programa s obzirom na povezane rezultate kliničkih ispitivanja,</P>
               <P>— ulaska novih proizvoda na tržište.</P>
            </SHORT_DESCR>
            <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            <NO_LOT_DIVISION/>
            <OBJECT_DESCR ITEM="1">
               <n2016:NUTS CODE="BE"/>
               <MAIN_SITE>
                  <P>Uglavnom u prostorima ugovaratelja.</P>
               </MAIN_SITE>
               <SHORT_DESCR>
                  <P>Vidjeti internetsku adresu navedenu u odjeljku I.3.</P>
               </SHORT_DESCR>
               <AC_QUALITY>
                  <AC_CRITERION>Kvaliteta predložene metodologije</AC_CRITERION>
                  <AC_WEIGHTING>70 bodova</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Organizacija rada i resursa</AC_CRITERION>
                  <AC_WEIGHTING>20 bodova</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_QUALITY>
                  <AC_CRITERION>Mjere kontrole kvalitete</AC_CRITERION>
                  <AC_WEIGHTING>10 bodova</AC_WEIGHTING>
               </AC_QUALITY>
               <AC_PRICE>
                  <AC_WEIGHTING>40</AC_WEIGHTING>
               </AC_PRICE>
               <NO_OPTIONS/>
               <EU_PROGR_RELATED>Obzor 2020.</EU_PROGR_RELATED>
               <INFO_ADD>
                  <P>Vidjeti internetsku adresu navedenu u odjeljku I.3.</P>
               </INFO_ADD>
            </OBJECT_DESCR>
         </OBJECT_CONTRACT>
         <PROCEDURE>
            <PT_OPEN/>
            <CONTRACT_COVERED_GPA/>
            <NOTICE_NUMBER_OJ>2017/S 150-309663</NOTICE_NUMBER_OJ>
         </PROCEDURE>
         <AWARD_CONTRACT ITEM="1">
            <CONTRACT_NO>LC-00689269</CONTRACT_NO>
            <TITLE>
               <P>Studija o utjecaju spajanja i preuzimanja vlasništva na inovacije u farmaceutskom sektoru</P>
            </TITLE>
            <AWARDED_CONTRACT>
               <DATE_CONCLUSION_CONTRACT>2018-01-11</DATE_CONCLUSION_CONTRACT>
               <NB_TENDERS_RECEIVED>14</NB_TENDERS_RECEIVED>
               <NB_TENDERS_RECEIVED_SME>6</NB_TENDERS_RECEIVED_SME>
               <NB_TENDERS_RECEIVED_NON_EU>0</NB_TENDERS_RECEIVED_NON_EU>
               <NB_TENDERS_RECEIVED_EMEANS>0</NB_TENDERS_RECEIVED_EMEANS>
               <NO_AWARDED_TO_GROUP/>
               <CONTRACTOR>
                  <ADDRESS_CONTRACTOR>
                     <OFFICIALNAME>Informa Pharma Consulting</OFFICIALNAME>
                     <ADDRESS>Christchurch Court, 10-15 Newgate Street</ADDRESS>
                     <TOWN>London</TOWN>
                     <POSTAL_CODE>EC1A 7AZ</POSTAL_CODE>
                     <COUNTRY VALUE="UK"/>
                     <n2016:NUTS CODE="UK"/>
                  </ADDRESS_CONTRACTOR>
                  <NO_SME/>
               </CONTRACTOR>
               <VAL_TOTAL CURRENCY="EUR">277800.00</VAL_TOTAL>
            </AWARDED_CONTRACT>
         </AWARD_CONTRACT>
         <COMPLEMENTARY_INFO>
            <ADDRESS_REVIEW_BODY>
               <OFFICIALNAME>Opći sud</OFFICIALNAME>
               <ADDRESS>Rue du Fort Niedergrünewald</ADDRESS>
               <TOWN>Luxemburg</TOWN>
               <POSTAL_CODE>L-2925</POSTAL_CODE>
               <COUNTRY VALUE="LU"/>
               <PHONE>+352 43031</PHONE>
               <E_MAIL>GeneralCourt.Registry@curia.europa.eu</E_MAIL>
               <FAX>+352 43032100</FAX>
               <URL>http://curia.europa.eu</URL>
            </ADDRESS_REVIEW_BODY>
            <REVIEW_PROCEDURE>
               <P>Vidjeti internetsku adresu navedenu u odjeljku I.3.</P>
            </REVIEW_PROCEDURE>
            <DATE_DISPATCH_NOTICE>2018-01-31</DATE_DISPATCH_NOTICE>
         </COMPLEMENTARY_INFO>
      </F03_2014>
   </FORM_SECTION>
</TED_EXPORT>
